Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study

Gynecologic Oncology

Volumn 119, Issue 3, 2010, Pages 444-450

  Hurteau, Jean A ^a   Brady, Mark F ^b   Darcy, Kathleen M ^b   McGuire, William P ^c   Edmonds, Pamela ^d,j   Pearl, Michael L ^e   Ivanov, Iouri ^f   Tewari, Krishnansu S ^g   Mannel, Robert S ^h   Zanotti, Kristine ⁱ   Benbrook, Doris M ^h  

^a UNIVERSITY OF CHICAGO   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c Harry and Jeanette Weinberg Cancer Institute   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

^e STONY BROOK UNIVERSITY   (United States)

^f Pathology Department   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

ⁱ UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^j ABINGTON MEMORIAL HOSPITAL   (United States)

more..

Author keywords

CA 125; Ovarian cancer; Recurrence; Tamoxifen; Thalidomide; VEGF

Indexed keywords

PLATINUM DERIVATIVE; TAMOXIFEN; TAXANE DERIVATIVE; THALIDOMIDE; VASCULOTROPIN;

ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER STAGING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE ESCALATION; ENDOCRINE DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; EYE DISEASE; FEMALE; GASTROINTESTINAL SYMPTOM; HEARING DISORDER; HUMAN; LEUKOPENIA; LIVER DISEASE; LUNG COMPLICATION; MAJOR CLINICAL STUDY; METABOLIC DISORDER; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE; NEUTROPENIA; ONCOLOGY; OVARY CANCER; OVERALL SURVIVAL; PAIN; PERIPHERAL NEUROPATHY; PERITONEUM CANCER; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SKIN DISEASE; SOMNOLENCE; THROMBOCYTOPENIA; TREATMENT RESPONSE; UROGENITAL TRACT DISEASE; UTERINE TUBE CARCINOMA; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRIDGED COMPOUNDS; CA-125 ANTIGEN; DISEASE-FREE SURVIVAL; ENDPOINT DETERMINATION; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; TAMOXIFEN; TAXOIDS; THALIDOMIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 78149358809     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.08.002     Document Type: Article

References (34)

1. M.K. Tuxen, G. Soletormos, and P. Dombernowsky Serum tumor marker CA 125 for monitoring ovarian cancer during follow-up Scand J Clin Lab Invest 62 2002 177 188
2. G.J. Rustin, and M.E. van der Burg A randomized trial in ovarian cancer of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OVO5/EORTC 55955 trials) J Clin Oncol 27 18S 2009 793s
3. S.A. Ghamande, M.H. Silverman, W. Huh, K. Behbakht, G. Ball, and L. Cuasay A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer Gynecol Oncol 111 2008 89 94
4. K.D. Hatch, J.B. Beecham, J.A. Blessing, and W.T. Creasman Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients Cancer 68 1991 269 271
5. M. Markman, K.A. Iseminger, K.D. Hatch, W.T. Creasman, W. Barnes, and B. Dubeshter Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report Gynecol Oncol 62 1996 4 6
6. S.M. Hyder, Z. Nawaz, C. Chiappetta, and G.M. Stancel Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor Cancer Res 60 2000 3183 3190
7. V.C. Jordan, S. Gapstur, and M. Morrow Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease J Natl Cancer Inst 93 2001 1449 1457
8. J. Matthews, and J.A. Gustafsson Estrogen signaling: a subtle balance between ER alpha and ER beta Mol Interv 3 2003 281 292
9. E.R. Levin Integration of the extranuclear and nuclear actions of estrogen Mol Endocrinol 19 2005 1951 1959
10. C. Zhao, K. Dahlman-Wright, and J.A. Gustafsson Estrogen receptor beta: an overview and update Nucl Recept Signal 6 2008 e003
11. M.P. Applanat, H. Buteau-Lozano, M.A. Herve, and A. Corpet Vascular endothelial growth factor is a target gene for estrogen receptor and contributes to breast cancer progression Adv Exp Med Biol 617 2008 437 444
12. R.J. D'Amato, M.S. Loughnan, E. Flynn, and J. Folkman Thalidomide is an inhibitor of angiogenesis Proc Natl Acad Sci USA 91 1994 4082 4085
13. J. Folkman Angiogenesis in cancer, vascular, rheumatoid and other disease Nat Med 1 1995 27 31
14. W.G. McBride Thalidomide and congenital abnormalities Lancet 2 1961 1358
15. W. Lenz Thalidomide and congenital abnormalities Lancet 1 1962 45
16. A.A. Kamat, T.J. Kim, C.N. Landen Jr., C. Lu, L.Y. Han, and Y.G. Lin Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer Cancer Res 67 2007 281 288
17. J.A. Nagy, A.M. Dvorak, and H.F. Dvorak VEGF-A and the induction of pathological angiogenesis Annu Rev Pathol 2 2007 251 275
18. C. Tempfer, A. Obermair, L. Hefler, G. Haeusler, G. Gitsch, and C. Kainz Vascular endothelial growth factor serum concentrations in ovarian cancer Obstet Gynecol 92 1998 360 363
19. C.A. Chen, W.F. Cheng, C.N. Lee, T.M. Chen, C.C. Kung, and F.J. Hsieh Serum vascular endothelial growth factor in epithelial ovarian neoplasms: correlation with patient survival Gynecol Oncol 74 1999 235 240
20. M.K. Oehler, and H. Caffier Prognostic relevance of serum vascular endothelial growth factor in ovarian cancer Anticancer Res 20 6D 2000 5109 5112
21. B.C. Cooper, J.M. Ritchie, C.L. Broghammer, J. Coffin, J.I. Sorosky, and R.E. Buller Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer Clin Cancer Res 8 2002 3193 3197
22. A. Harlozinska, P. Sedlaczek, J. Kulpa, M. Grybos, E. Wójcik, and A. Van Dalen Vascular endothelial growth factor (VEGF) concentration in sera and tumor effusions from patients with ovarian carcinoma Anticancer Res 24 2004 1149 1157
23. L. Li, L. Wang, W. Zhang, B. Tang, J. Zhang, and H. Song Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer Anticancer Res 24 3b 2004 1973 1979
24. L.A. Hefler, R. Zeillinger, C. Grimm, A.K. Sood, W.F. Cheng, and A. Gadducci Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer Gynecol Oncol 103 2006 512 517
25. B. Abendstein, G. Daxenbichler, G. Windbichler, A.G. Zeimet, A. Geurts, and F. Sweep Predictive value of uPA, PAI-1, HER-2 and VEGF in the serum of ovarian cancer patients Anticancer Res 20 1B 2000 569 572
26. A. Alvarez Secord, R. Sayer, S.A. Snyder, G. Broadwater, G.C. Rodriguez, and A. Berchuck The relationship between serum vascular endothelial growth factor, persistent disease, and survival at second-look laparotomy in ovarian cancer Gynecol Oncol 94 2004 74 79
27. A.A. Garcia, H. Hirte, G. Fleming, D. Yang, D.D. Tsao-Wei, and L. Roman Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia J Clin Oncol 26 2008 76 82
28. R.J. Schilder, M.W. Sill, R.B. Lee, T.J. Shaw, M.K. Senterman, and A.J. Klein-Szanto Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study J Clin Oncol 26 2008 3418 3425
29. E.S. Han, R.A. Burger, K.M. Darcy, M.W. Sill, B.E. Greer, and J.I. Sorosky Relationship between angiogenic markers and clinicopathologic factors/outcome in GOG-170D, a phase II trial of bevacizumab (Bev) in recurrent or persistent epithelial ovarian cancer (EOC) and primary peritoneal cancer (PPC) J Clin Oncol 26 2008 (ASCO Abstract #5577)
30. A. Dmoszyńska, A. Bojarska-Junak, D. Domański, J. Roliński, M. Hus, and M. Soroka-Wojtaszko Production of proangiogenic cytokines during thalidomide treatment of multiple myeloma Leuk Lymphoma 43 2002 401 406
31. M. Melchert, and A. List The thalidomide saga Int J Biochem Cell Biol 39 2007 1489 1499
32. K.L. Blackwell, Z.A. Haroon, S. Shan, W. Saito, G. Broadwater, and C.S. Greenberg Tamoxifen inhibits angiogenesis in estrogen receptor-negative animal models Clin Cancer Res 6 2000 4359 4364
33. Y. Yin, S. Wang, Y. Sun, Y. Matt, N.H. Colburn, and Y. Shu JNK/AP-1 pathway is involved in tumor necrosis factor-alpha induced expression of vascular endothelial growth factor in MCF7 cells Biomed Pharmacother 63 2009 429 435
34. W.H. Kruskal, and W.A. Wallis Use of ranks on one-criterion variance analysis J Am Stat Assoc 47 1952 583-21